Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01466764 · ClinicalTrials.gov registry record · NA
Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain
A NA study, sponsored by Stanford University.
- Terminated
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT01466764: Clinical Trial NA study, sponsored by Stanford University.
NCT01466764 is a NA study that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01466764, a NA study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of postoperative incisional pain.
Primary Outcome
Tissue samples were collected at the surgical wound site at 3 time points during the 1st 72 hours following surgery. Tissue samples from subjects receiving placebo, and subjects receiving anakinra injections pre, and post op were analyzed for IL-1
Interventions
- OTHER Normal Saline
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-06 |
| Phase | NA |
Why NCT01466764 stopped before completion
NCT01466764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT01466764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01466764 about?
NCT01466764 is a clinical study titled "Immunomodulation, IL-1 Inhibition, and Postoperative Incisional Pain". The investigators hypothesize that perioperative administration of anakinra will reduce incisional pain by lowering the concentration of inflammatory mediators in surgical wounds. This knowledge is important because it suggests a new, previously unexplored pharmacological target for the control of p...
What is the current status of trial NCT01466764?
This trial is currently terminated. It is a NA study. The enrollment target is 13 participants. The study started on 2011-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01466764?
The interventions under investigation include: Normal Saline (OTHER), Anakinra (DRUG).
Who is sponsoring clinical trial NCT01466764?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01466764's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia